Core Insights - Tonix Pharmaceuticals achieved FDA approval and launched TONMYA, the first new medicine for fibromyalgia in over 15 years, with over 1,500 healthcare providers prescribing it to approximately 2,500 patients by February 27, 2026 [2][4] - The company reported a net product revenue of approximately $13.1 million for the full year 2025, an increase from $10.1 million in 2024, with TONMYA contributing approximately $1.4 million from its launch until year-end [17][19] - Tonix has a robust clinical pipeline, including TNX-4800 for Lyme disease prevention and TNX-102 SL for major depressive disorder, with plans for further development and FDA discussions in 2026 [2][6][9] Commercial Updates - TONMYA was launched on November 17, 2025, and has shown favorable early prescription trends, with cumulative prescriptions totaling approximately 4,200 by February 27, 2026 [4][3] - The company has deployed a salesforce of approximately 90 members to support the commercialization of TONMYA and enhance awareness among healthcare providers and patients [2][4] Financial Highlights - As of December 31, 2025, Tonix had approximately $207.6 million in cash and cash equivalents, a significant increase from $98.8 million in 2024 [13][30] - The company completed a $20.0 million registered direct offering with Point72 in December 2025 to fund commercialization and pipeline development [14] - Research and development expenses for 2025 were approximately $44.5 million, reflecting increased investment in pipeline projects [18] Product Pipeline - TNX-4800, a long-acting monoclonal antibody for Lyme disease prevention, is set for FDA discussions regarding Phase 2/3 development in 2026 [6][9] - TNX-102 SL has received IND clearance for a Phase 2 study in major depressive disorder, with enrollment expected to begin in mid-2026 [9][12] - TNX-2900, targeting Prader-Willi syndrome, is planned for a Phase 2 trial initiation in Q1 2027 [11] Operational Highlights - The company has established partnerships for distribution and patient access programs to facilitate the commercialization of TONMYA [8] - Tonix is focusing on expanding payer engagement and establishing contracts with commercial payers while progressing discussions with Medicare and Medicaid [8]

Core Insights - Tonix Pharmaceuticals has launched TONMYA (cyclobenzaprine HCl sublingual tablets) for fibromyalgia treatment, marking the first new prescription medicine for this condition in over 15 years [2][7] - The drug demonstrated statistically significant pain reduction in Phase 3 trials and was well tolerated by patients [1][2] Company Overview - Tonix Pharmaceuticals is a fully integrated biotechnology company focused on central nervous system (CNS) and immunology treatments, addressing high unmet medical needs [8] - The company’s flagship product, TONMYA, is supported by a commercial infrastructure that includes other marketed products for acute migraine [8] Product Details - TONMYA is designed to provide rapid absorption and reduce the formation of the active metabolite norcyclobenzaprine, which can interfere with treatment durability [2][6] - The FDA approved TONMYA in August 2025 based on the results of the Phase 3 RESILIENT trial, which involved 457 patients [2][7] Clinical Trial Results - The Phase 3 RESILIENT trial showed a statistically significant reduction in mean daily pain at 14 weeks, with an increase in the number of patients achieving a 30% reduction in pain compared to placebo [2] - Common adverse events were mild and primarily related to oral cavity reactions, leading to low withdrawal rates from the study [2] Market Context - Fibromyalgia affects an estimated 6-12 million adults in the U.S., with a significant majority being women, and is characterized by chronic pain, fatigue, and sleep disturbances [5] - Current FDA-approved treatments for fibromyalgia are limited by side effects and high discontinuation rates, positioning TONMYA as a promising alternative [2][5]

Core Insights - Tonix Pharmaceuticals has launched TONMYA (cyclobenzaprine HCl sublingual tablets) for fibromyalgia treatment, marking the first new prescription medicine for this condition in over 15 years [2][7] - The drug demonstrated statistically significant pain reduction in Phase 3 trials and was well tolerated by patients [1][2] Company Overview - Tonix Pharmaceuticals is a fully integrated biotechnology company focused on central nervous system (CNS) and immunology treatments, with TONMYA as its flagship product [8] - The company is also developing other treatments, including those for major depressive disorder and acute stress disorder, alongside its immunology pipeline [8] Product Details - TONMYA is designed to provide rapid absorption and reduce the formation of the active metabolite norcyclobenzaprine, which can interfere with treatment efficacy [2][6] - The FDA approved TONMYA in August 2025 based on the results of the Phase 3 RESILIENT trial, which involved 457 patients [2][7] Clinical Trial Results - The Phase 3 RESILIENT trial showed a statistically significant reduction in mean daily pain at 14 weeks, with a notable increase in patients achieving a 30% reduction in pain compared to placebo [2] - Common adverse events were mild and primarily related to oral cavity reactions, leading to minimal study withdrawals [2] Market Context - Fibromyalgia affects an estimated 6-12 million adults in the U.S., predominantly women, and is characterized by chronic pain, fatigue, and sleep disturbances [5] - Current FDA-approved treatments for fibromyalgia have limitations related to side effects and adherence, positioning TONMYA as a promising alternative [2][5]

Core Insights - Tonix Pharmaceuticals Holding Corp. announced a poster presentation for its product Tonmya™ (cyclobenzaprine HCl sublingual tablets) at the 2026 AAPM PainConnect Annual Meeting, highlighting its significance in treating fibromyalgia [1][3]. Company Overview - Tonix Pharmaceuticals is a fully-integrated, commercial-stage biotechnology company focused on central nervous system (CNS) and immunology treatments, addressing areas of high unmet medical need [3]. - The company’s flagship medicine, Tonmya, is the first new treatment for fibromyalgia in over 15 years [3]. - Tonix's CNS commercial infrastructure supports marketed products, including acute migraine treatments Zembrace® SymTouch® and Tosymra® [3]. Product Development - Tonix is conducting Phase 2 clinical trials to evaluate Tonmya's potential in major depressive disorder and acute stress disorder [3]. - The company is advancing TNX-2900, which is Phase 2 ready for treating Prader-Willi syndrome, a rare disease [3]. - Tonix is also developing immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for preventing kidney transplant rejection [3].

Core Viewpoint - Tonix Pharmaceuticals has received approval to transfer its common stock listing from the Nasdaq Capital Market to the Nasdaq Global Select Market, effective March 3, 2026, which may enhance its visibility and liquidity among institutional investors [1][2]. Group 1: Company Overview - Tonix Pharmaceuticals is a fully integrated, commercial-stage biotechnology company focused on central nervous system (CNS) and immunology treatments for high unmet medical needs [3]. - The company's flagship product, TONMYA™ (cyclobenzaprine HCl sublingual tablets 2.8mg), is the first new treatment for fibromyalgia in over 15 years [3]. - Tonix's CNS portfolio includes products for acute migraine and ongoing clinical trials for major depressive disorder and acute stress disorder [3]. Group 2: Market Position and Future Outlook - The uplisting to the Nasdaq Global Select Market signifies compliance with higher financial and corporate governance standards, potentially leading to increased trading volumes and access to institutional investors [2]. - The company aims to leverage this enhanced market position to drive growth and create shareholder value [2].

Core Insights - Tonix Pharmaceuticals Holding Corp. is participating in two investor conferences in March 2026, highlighting its engagement with the investment community [1][2]. Group 1: Upcoming Conferences - The company will present at the TD Cowen 46th Annual Healthcare Conference on March 4, 2026, with CEO Seth Lederman as the presenter [1]. - Management will be available for one-on-one meetings at the Barclays 28th Annual Healthcare Conference from March 10 to 12, 2026 [2]. Group 2: Company Overview - Tonix Pharmaceuticals is a fully integrated, commercial-stage biotechnology company focused on treatments for central nervous system (CNS) and immunology conditions [3]. - The company's flagship product, TONMYA™ (cyclobenzaprine HCl sublingual tablets 2.8mg), is the first new treatment for fibromyalgia in over 15 years [3]. - Tonix is advancing its CNS portfolio, including products for acute migraines and ongoing Phase 2 clinical trials for major depressive disorder and acute stress disorder [3]. - The company is also developing immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500 for kidney transplant rejection prevention [3].

Core Viewpoint - Tonix Pharmaceuticals Holding Corp. is actively engaging with investors through presentations and meetings at various conferences in January 2026, showcasing its innovative pipeline and marketed products in the biotechnology sector [1][2][3]. Company Overview - Tonix Pharmaceuticals is a fully integrated biotechnology company with marketed products and a robust pipeline of development candidates [4]. - The company markets FDA-approved TONMYA™, a first-in-class, non-opioid analgesic for fibromyalgia, which is the first new prescription medicine approved for this condition in over 15 years [4]. - Tonix also offers treatments for acute migraine, including Zembrace® SymTouch® and Tosymra® [4]. Product Pipeline - Tonix's development portfolio focuses on central nervous system (CNS) disorders, immunology, immuno-oncology, rare diseases, and infectious diseases [4]. - Key candidates include: - TNX-102 SL for acute stress reaction and major depressive disorder [4]. - TNX-1500, a Phase 2-ready monoclonal antibody for organ transplant rejection and autoimmune diseases [4]. - TNX-2900 for Prader-Willi syndrome, expected to start a pivotal Phase 2 study in 2026 [4]. - TNX-801, a vaccine for mpox and smallpox, and TNX-4800, a monoclonal antibody for Lyme disease prevention [4]. - TNX-4200, a broad-spectrum antiviral agent with a contract for up to $34 million from the U.S. Department of Defense [4]. Upcoming Conferences - Tonix's management will present at the Sachs Associates 9th Annual Neuroscience Innovation Forum on January 11, 2026, and at the Biotech Showcase 2026 on January 13, 2026 [2][3]. - The presentations will be led by Seth Lederman, M.D., the President and CEO of Tonix Pharmaceuticals [2][3]. Investor Relations - Investors interested in meetings with the company's management during the conferences can contact the provided email [4]. - Additional information about Tonix and its products can be found on the company's website [6].

Core Insights - Tonix Pharmaceuticals is anticipating FDA approval for TNX-102SL for fibromyalgia by August 15, 2025, which would mark the first new drug for this condition in over 16 years [1][2] - The company reported a cash position of $125.3 million as of June 30, 2025, which is expected to fund operations into the third quarter of 2026 [1][8][9] - Recent Phase 3 trial results for TNX-102SL demonstrated statistically significant pain reduction in fibromyalgia patients, supporting the ongoing New Drug Application (NDA) review [5][10] Company Overview - Tonix Pharmaceuticals is a fully-integrated biotechnology company focused on developing therapies for pain management and vaccines for public health challenges, with a strong emphasis on central nervous system disorders [15] - The company has a diverse pipeline, including TNX-102SL for fibromyalgia and acute stress reactions, TNX-1500 for organ transplant rejection, and TNX-801 as a vaccine candidate [15][6] Financial Performance - For the second quarter of 2025, Tonix reported net product revenue of approximately $2.0 million, a slight decrease from $2.2 million in the same period of 2024 [10] - Research and development expenses increased to $10.8 million in Q2 2025 from $9.7 million in Q2 2024, primarily due to heightened clinical and manufacturing costs [11] - Selling, general, and administrative expenses rose significantly to $16.2 million in Q2 2025, compared to $7.5 million in Q2 2024, reflecting increased spending on pre-launch activities for TNX-102SL [12] Pipeline Developments - The company is advancing TNX-102SL for acute stress reaction and acute stress disorder, with the first patient dosed in the OASIS trial funded by the U.S. Department of Defense [4][15] - TNX-1500 has shown positive Phase 1 results and is being prepared for a Phase 2 study targeting kidney transplant rejection [6] - TNX-801 has demonstrated durable protection in animal models against mpox and rabbitpox, supporting its potential as a vaccine candidate [6] Market Position - In June 2025, Tonix was added to the Russell 3000® and Russell 2000® Indexes, enhancing its visibility among institutional investors as it approaches key regulatory milestones [1][13]

Core Insights - Tonix Pharmaceuticals Holding Corp. presented new findings on TNX-801, a recombinant horsepox live virus vaccine, demonstrating its potential for durable immunity against mpox and smallpox with significantly reduced virulence compared to traditional vaccines [1][2][3] Group 1: TNX-801 Vaccine Development - TNX-801 is shown to be up to 100,000-fold less virulent than live smallpox vaccine strains, providing robust immunogenicity and protection for over one year in animal studies [1][2] - Subcutaneous administration of TNX-801 offers equivalent protection to traditional percutaneous methods, potentially reducing risks of administration-site infections and scarring [2][3] - Preclinical studies indicate that a single dose of TNX-801 generates strong antibody responses across various animal models, including immunocompromised subjects, with all vaccinated macaques surviving lethal mpox challenges [2][3] Group 2: Strategic Importance and Future Directions - The vaccine's unique risk-benefit profile may make it a critical tool for public health, particularly in response to mpox outbreaks and potential smallpox threats [2][3] - Tonix Pharmaceuticals aims to advance TNX-801 into clinical evaluation, focusing on subcutaneous delivery to streamline vaccination processes [2][3] - The ongoing classification of mpox as a public health concern by organizations like the WHO and CDC underscores the importance of developing effective vaccines like TNX-801 [3] Group 3: Company Overview - Tonix Pharmaceuticals is a fully integrated biopharmaceutical company with a focus on pain management therapies and vaccines for public health challenges [4] - The company is advancing TNX-102 SL for fibromyalgia management, with a PDUFA goal date of August 15, 2025, for marketing authorization [4] - Tonix's infectious disease portfolio includes TNX-801 and TNX-4200, the latter being a broad-spectrum antiviral agent with a contract worth up to $34 million from the U.S. Department of Defense [4]

Core Insights - The combination treatment of mTNX-1700 with anti-PD1 antibody has shown increased survival and decreased metastases in animal models of gastric cancer compared to anti-PD1 treatment alone [1][3] - mTNX-1700 activates cancer-killing CD8+ T cells and limits neutrophil-mediated immune evasion, indicating its potential in overcoming resistance to anti-PD-1 immunotherapy [1][2] Company Overview - Tonix Pharmaceuticals Holding Corp. is a fully-integrated biopharmaceutical company with marketed products and a pipeline of development candidates, focusing on immunology and oncology [1][7] - The company is developing TNX-1700, a fusion protein for the treatment of gastric and colorectal cancers, under a license from Columbia University [4][5] Research Findings - The study published in Cancer Cell demonstrates that mTNX-1700 in combination with anti-PD-1 therapy shrank primary tumors, reduced liver and lung metastases, and increased survival in mouse models [2][3] - The research highlights the role of Trefoil Factor 2 (TFF2) in reducing immunosuppressive neutrophils and enhancing anti-tumoral CD8+ T cell responses [3][4] Future Development - Tonix Pharmaceuticals aims to further develop TNX-1700 to address the challenges of anti-PD-1 resistant cancers, with ongoing studies to identify potential clinical biomarkers [2][3] - The collaboration with Columbia University is expected to enhance understanding of TFF2's role in the tumor microenvironment and its impact on immunotherapy resistance [3][4]